Colombia and Africa's New Cannabis Export Corridor to Germany

October 24, 2026

Photo by Mark Stebnicki via Pexels.

Pull up Germany's Federal Institute for Drugs and Medical Devices (BfArM) import figures for 2025 and the shape of the next five years of global cannabis trade is already sitting there in the numbers, not buried in some analyst's projection deck. German pharmacies sold through more than €1 billion worth of medical cannabis last year for the first time ever, and the raw tonnage flowing into the country to supply that demand has stopped behaving like a niche medical program and started behaving like a commodity import market -- the kind with price compression, origin competition, and procurement officers squeezing every euro-cent out of a per-gram contract.

That price compression is the part worth sitting with. Industry pricing analysis has per-gram landed cost approaching €4 by late 2026, down from levels that made established greenhouse flower exporters comfortably competitive just a couple years ago. Compression like that doesn't just shrink margins evenly across the board -- it reshuffles who can even stay in the game, and it reshuffles toward whoever grows the cheapest compliant flower, not whoever got there first.

Two regions are positioned to benefit from exactly that reshuffle: Colombia, with its equatorial sun and a flower-export logistics backbone inherited from the cut-flower trade, and southern Africa, led by Lesotho and South Africa, both of which built licensed cultivation sectors from scratch over the past eight years specifically with export in mind. This isn't a forecast about some distant hypothetical market. German import data from Q3 2025 through Q1 2026 already shows Colombian and South African volumes climbing quarter over quarter while the incumbents' combined share erodes. The question this piece is actually asking isn't whether the shift is happening -- it's how far it goes and how fast.

Germany's Import Boom Is the Whole Ballgame

German medical cannabis imports fluctuated sharply across recent quarters, jumping from 34.1 tonnes in Q2 2025 to a peak of 60.8 tonnes in Q4 2025 before easing to 50.5 tonnes in Q1 2026, with the 2024 full-year total at 72 tonnes.

Start with the headline number: Germany imported 56.9 tonnes of medical cannabis in the third quarter of 2025 alone, an all-time quarterly high and nearly 20% more than the quarter before it. That's not a one-off spike -- it's the continuation of a curve that's been bending upward all year. The first nine months of 2025 brought in 142 tonnes, compared to just 72 tonnes for the entirety of 2024. Germany effectively doubled a full year's worth of imports in three quarters.

Full-year 2025 landed around 201 tonnes, and the early 2026 data suggests the growth rate, while still positive, is leveling off from its steepest climb: Q4 2025 was revised upward to 60.772 tonnes, and BfArM's Q1 2026 figure came in at 50.539 tonnes. Read that as a market finding a higher plateau rather than a bubble popping -- the quarter-over-quarter dip from Q4 to Q1 is modest and could easily reflect normal seasonal pharmacy ordering patterns rather than any slackening in underlying demand.

What makes this more than an interesting cultivation-volume story is the commercial side: German pharmacy sell-out sales crossed €1 billion in 2025 for the first time. That threshold matters because it moves medical cannabis out of the category of a tolerated medical exception and into the category of a product line that insurers, wholesalers, and pharmacy chains build procurement strategy around. A billion-euro category attracts serious capital and serious competition for supply contracts in a way a hundred-million-euro program never did.

And that's exactly where the tension in this article lives. Canada and Portugal, the two earliest and most established exporters to Germany, still hold roughly 80% combined market share as of early 2026. That's a dominant position by any normal measure. But it's a share that's been eroding quarter by quarter as newer, lower-cost origins start winning tender volume, and an 80% share that's shrinking is a very different competitive position than an 80% share that's stable. The rest of this piece is about who's taking the other 20%, and why the math says that slice is going to keep growing.

Why Price, Not Pedigree, Now Decides Market Share

Photo by mrchrisby via Unsplash.

Here's the number that explains almost everything else in this article: industry pricing analysis has the average per-gram price breaching €5 and drifting down toward roughly €4 by late 2026. For a market that was pricing flower well above that not long ago, that's a meaningful compression, and it creates something close to a hard line in the sand for producers. Origins that can land product in Germany below about €2.50 per gram are solidly viable. Origins landing above roughly €3.50 per gram start losing tenders, full stop, regardless of brand reputation or how long they've been in the market.

Canada and Portugal didn't win their early dominance on production cost -- they won it on being first through the regulatory door and having logistics and certification infrastructure already built out while other countries were still drafting their cannabis laws. That's a legitimate first-mover advantage, but it's not the same thing as a cost advantage, and the two tend to diverge once a market matures. Labor and energy costs for Canadian and Portuguese greenhouse cultivation are structurally higher than labor and energy costs in Lesotho's highlands or Colombia's growing regions, where sun-grown or lightly-assisted cultivation needs far less artificial lighting and heating to hit the same yield.

This is a familiar pattern to anyone who's watched other horticultural commodities mature. Coffee and cut flowers both went through the same transition: early production clustered wherever infrastructure and trade relationships existed first, and then, once quality certification and shipping logistics standardized across more origin countries, production cost became the deciding factor and cultivation migrated toward the cheapest compliant equatorial growing regions. Colombia and Kenya didn't become flower-export powerhouses by accident -- they became powerhouses once the certification and logistics barriers that used to protect established growers stopped being a moat.

The honest counter-case here is that price isn't the only variable German buyers weight. Pharmacies and insurers care about consistent batch-to-batch THC and CBD content, reliable audit history, and supply security -- a cheaper shipment that arrives late or fails a potency spec check costs a pharmacy more in disruption than it saves in per-gram price. Newer entrants haven't yet built the multi-year audit track record that Canadian and Portuguese suppliers have, and that track record is worth real money in a procurement decision. Price is pulling the market in one direction; proven reliability is still pulling back in the other.

Colombia's Quiet Comeback

Colombia's numbers in the German import data read almost like a late start finally catching fire. The country shipped just 0.1 tonnes to Germany in the second quarter of 2025. By the third quarter, that figure was 1.2 tonnes -- a twelve-fold jump in a single quarter. Full-year 2025 exports reached 3.5 tonnes, up 447% year over year, with most of that growth concentrated in the final quarter of the year. Colombia's share of the German import market rose from under 1% in 2024 to nearly 2% in Q1 2026. That's still a small slice of a market where Canada and Portugal hold roughly 80% between them -- but a trajectory that steep, this early in a country's export ramp, is the kind of signal that tends to matter more than the absolute number.

The legal architecture behind Colombia's export sector is Law 1787 of 2016, which created the licensed cannabis framework, and Decree 811 of 2021, which refined cultivation and export rules. Export quotas are issued on a per-shipment basis, and the national health regulator INVIMA handles sanitary registration separately. That's a more cumbersome system than Canada's standing export licenses, which authorize ongoing shipment volumes rather than requiring approval shipment by shipment -- and it's a real friction cost Colombian exporters have to absorb that their Canadian competitors don't.

There's an unusual silver lining buried in Colombia's domestic politics, though. A bill that would legalize adult-use cannabis and open a domestic pharmacy-flower retail market has been stalled in Congress for years with no clear path to passage. That's bad news for anyone hoping to build a Colombian retail brand, but it's arguably good news for export-focused operators like Clever Leaves and NatuEra: with no domestic retail market pulling capital and management attention toward building local brands and dispensary relationships, those companies' entire operational focus stays on export quality, compliance, and winning German tenders. It's a narrower bet, but a more disciplined one.

Underneath all of this sits a genuine structural advantage: equatorial sun that cuts lighting costs dramatically, cannabis-cultivation labor costs well below levels seen in more established exporting markets, and flower-export logistics infrastructure -- cold chain, air freight relationships, phytosanitary certification experience -- that Colombia already built over decades as one of the world's largest cut-flower exporters. That's precisely the cost structure the price-compression dynamic described above rewards.

Lesotho and South Africa Build Out Supply

Lesotho has a four-year head start on almost every other cannabis exporter in Africa -- it licensed cultivation back in 2017, making it the continent's first mover by a wide margin. Industry-reported figures put the country's annual cannabis export revenue in the range of USD 15-20 million, split roughly 65% dried flower, 25% high-value extracts, and 10% seeds. Worth flagging plainly: that breakdown comes from industry reporting, not an independently audited government dataset, so treat the split as directionally useful rather than exact.

A regulatory shift in 2025 is worth watching closely. An amendment raised the cost of an operator licence in Lesotho to roughly M400,000 (Lesotho maloti, pegged 1:1 to the South African rand) according to a June 2026 industry analysis. That's a steep jump, and the predictable effect of steep licence-fee increases in any regulated agricultural sector is consolidation: larger, better-capitalized operators can absorb the cost and smaller domestic growers often can't. Zimbabwe and other early movers in global cannabis and hemp licensing have seen similar dynamics play out -- licence costs that look reasonable on paper price out exactly the smallholder growers that early reform advocates hoped would benefit most.

South Africa, meanwhile, is accelerating faster than Lesotho in the German data specifically. South African shipments to Germany rose 54% to reach 3.7 tonnes for full-year 2025, up 252% year over year. Q1 2026 alone brought in 1,045 kilograms -- putting South Africa on pace to exceed its entire 2025 total within a single calendar year if that run rate holds. Lesotho's shipments grew too, up 34% over the same comparison window, a real but comparatively slower growth rate next to South Africa's sharper acceleration.

It's tempting to read this as continent-wide momentum, but the data doesn't quite support that yet. Zimbabwe, Malawi, Zambia, Ghana, Eswatini, and Rwanda all have cannabis licensing regimes on paper, some dating back several years. Public export data from any of them to Germany or other major European markets remains thin to nonexistent. The honest framing is that the African side of this corridor currently runs through two countries, not a continent, and whether it broadens out over the next five to seven years is genuinely an open question rather than an assumed outcome.

What Could Stall This -- and What Would Confirm It

Photo by Peter_Lindenau via Pixabay.

The bull case for this corridor has real numbers behind it, not just enthusiasm. IMARC Group projects Africa's medical cannabis market growing from USD 1.9 billion in 2025 to USD 8.2 billion by 2034, a 17.2% compound annual growth rate. If that projection is directionally accurate -- and it's worth treating it as a projection, not a guarantee -- it implies sustained capital continuing to flow into Lesotho and South African cultivation capacity across exactly the mid-term window this article is concerned with.

The historical pattern backing this up is the same one referenced earlier: cut flowers and coffee both show that once a commodity standardizes under common quality certification across multiple origin countries, production migrates toward the cheapest compliant growing region over a window of roughly five to ten years. Colombia and Kenya's rise in cut flowers, and the broader shift of coffee production toward lowest-cost equatorial origins, both followed that timeline. What's unfolding in German cannabis imports right now is tracking that same clock, just a few years into it.

The bear case deserves equal weight, though. Lesotho's licence-cost hike to roughly M400,000 could concentrate production in a handful of large operators rather than producing the broad-based growth IMARC's projection implicitly assumes -- a consolidated industry with fewer, larger players doesn't necessarily grow export volume as fast as a more fragmented one scrambling to compete for market share. Currency and logistics volatility are real costs too: Lesotho is landlocked and depends on South African ports and rail for export, and South Africa's own port and rail congestion has been a persistent drag on agricultural exporters generally, not just cannabis. Those frictions rarely show up cleanly in per-gram production-cost estimates, but they show up in delayed shipments and blown delivery windows.

Colombia's stalled domestic reform cuts both ways as well. It's currently a feature -- it keeps capital and management focus locked on export quality rather than splitting attention toward building a domestic retail brand. But if that bill never passes, Colombia forgoes the kind of domestic demand base that let Canada's cannabis industry scale capital, cultivation expertise, and management talent at home before it ever had to compete internationally. A purely export-dependent industry is more exposed to a single buyer market's policy and pricing decisions than one with a domestic base to fall back on.

And Germany's own demand curve is the wildcard nobody should ignore. Price compression toward €4 per gram could reflect healthy competition -- or it could reflect oversupply risk, if German consumption growth doesn't keep pace with the number of new origin countries entering the tender process. Oversupply would hurt low-margin producers everywhere, new entrants and incumbents alike, not just the countries this article is betting on. The single most useful number for readers to track going forward is Colombia and South Africa's combined share of German imports, quarter over quarter -- crossing roughly 5% combined within the next two years would be a strong signal this corridor is structural rather than a 2025 blip.

Strip away the geography and the politics, and what's actually sorting this market is pharmacy procurement arithmetic. Whoever can land certified cannabis in Germany at roughly €2.50 to €3.50 per gram wins the next several years of contracts, and right now that math increasingly favors Bogotá and Maseru over the established exporters. That's not a prediction about brand loyalty or national reputation -- it's a prediction about spreadsheets at German wholesale distributors, and spreadsheets don't care who got there first.

The more useful way to think about this corridor is as a preview rather than a one-off story. Germany is the first truly large national cannabis import market to mature past its early scarcity phase into genuine price competition, but it won't be the last. Whenever the next Germany-sized market opens -- whether that's a European neighbor loosening its own medical import rules or a larger adult-use market eventually opening legal import channels -- the same cost-driven sorting is likely to repeat, probably on a similar multi-year timeline. The countries positioning their export infrastructure and certification now, before that next market opens, are the ones likely to capture early share the way Colombia and South Africa are capturing it in Germany today.

The more speculative bet, and one worth holding loosely: if Lesotho's licence-cost consolidation pattern continues and spreads to other African entrants as they formalize their export frameworks, the long-run winners in this corridor may end up being a fairly small number of large, well-capitalized operators per country -- not the broad smallholder farming sector that a lot of early cannabis-reform advocates in Africa hoped legalization would build. That's not a certainty, and it's worth watching the licensing fee structures in Zimbabwe, Malawi, and the other names in this space as the real tell for whether that pattern holds or whether some of them chart a more accessible path for smaller growers.